Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Opthea Limited ( (AU:OPT) ) just unveiled an update.
Opthea Limited has announced the quotation of new securities on the ASX, specifically 407 ordinary fully paid securities, following the exercise of options or conversion of other convertible securities. This move may impact Opthea’s market presence by potentially increasing its capital base and providing additional funds for its ongoing and future projects, which could enhance its competitive position in the biotech market.
More about Opthea Limited
Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company’s primary products are aimed at addressing retinal diseases, with an emphasis on innovative treatments that target unmet medical needs in the ophthalmology market.
YTD Price Performance: 0.0%
Average Trading Volume: 9,900
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $790.3M
For an in-depth examination of OPT stock, go to TipRanks’ Stock Analysis page.
